Detecting leftover cancer cells after prostate removal
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new way to find microscopic cancer cells (minimal residual disease) in the blood after prostate surgery. If successful, it could help doctors decide if additional treatment is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have high-risk prostate cancer (PSA >20, Gleason 8-10, or tumor that has spread beyond the prostate on MRI or PSMA-PET).
- You are scheduled for robot-assisted surgery to remove your prostate.
- You agree to give samples of your prostate tissue and blood for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood test that finds tiny amounts of remaining cancer (called minimal residual disease) can help predict how well treatment works for men with prostate cancer that has spread. If you qualify, you'll help researchers understand if this test can guide future treatment decisions.
This trial tests a new microscope that helps surgeons see if any cancer is left at the edge of the removed prostate during surgery. It may help guide treatment right away, possibly reducing the need for more surgery or radiation later.
This study looks for tiny traces of cancer left in the body after treatment and surgery. It may help doctors understand if the cancer could come back, so it can be caught and treated earlier.
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
This trial studies prostate cancer cells in the blood (“circulating tumor cells”) while you undergo planned prostate surgery. It may help doctors better understand prostate cancer and how it behaves early, which could guide future treatment decisions.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.